SARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are
spreading globally with alarming persistence. Whether the mutations and evolution of spike …

Most available neutralizing antibodies are ineffective against highly mutated SARS-CoV-2
Omicron subvariants. Therefore, it is crucial to develop potent and broad-spectrum …

Despite development of effective SARS-CoV-2 vaccines, a sub-group of vaccine non-
responders depends on therapeutic antibodies or small-molecule drugs in cases of severe …

Influenzavirus is among the most relevant candidates for a next pandemic. We review here
the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly …

Blood transfusions from convalescent Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) infected patients could be used to treat patients with severe infections or …

The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of
effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the …

Viruses utilize host cells at all stages of their life cycle, from the transcription of genes and
translation of viral proteins to the release of viral copies. The human immune system …

Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the …

Introduction Monoclonal antibody (mAb) therapies proved safe and effective in preventing
progression of COVID-19 to hospitalization, but most were eventually defeated by continued …

Objectives The evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2) necessitates rapid methods for assessing monoclonal antibody (mAb) potency against …